Evidence map›Paper›PMID 41270093›Full record

ArticlePloS one2025

Serum IgG titer findings for Fusobacterium nucleatum associated with clinical outcome following surgery in patients with esophageal squamous cell carcinoma.

Toru Yoshikawa, Hiromi Nishi, Manabu Emi, Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Manato Ohsawa, Nao Kitasaki, Hitoshi Komatsuzawa and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Toru YoshikawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Hiromi NishiDepartment of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-0741-9886
Manabu EmiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Yoichi HamaiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Yuta IbukiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Tomoaki KurokawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Ryosuke HirohataDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Manato OhsawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Nao KitasakiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Hitoshi KomatsuzawaDepartment of Bacteriology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroyuki KawaguchiDepartment of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan.
Morihito OkadaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fusobacterium nucleatum (Fn) is known as an etiological factor related to periodontitis. However, recent reports have shown that it also functions as an oncogenic pathogen and is associated with progression of various cancers as well as poor prognosis of esophageal squamous cell carcinoma (ESCC) patients. The present study was conducted to examine the correlations of serum IgG antibody titer level against Fn (IgG-Fn) with clinicopathological characteristics, oral conditions, and survival outcomes in 305 patients who underwent an esophagectomy procedure for ESCC. The results revealed that 40.7% of the patients tested positive for IgG-Fn, and those in the positive group had significantly lower rates of overall survival (OS) and cancer-specific survival (CSS) as compared to patients who tested negative (OS; p = 0.01, CSS; p = 0.02). Multivariate analysis showed IgG-Fn positivity as an independent predictor of CSS (hazard ratio, 1.96; 95% CI, 1.32-2.90; p < 0.001). Moreover, among patients who were diagnosed with stage II-IV and underwent neoadjuvant therapy (NAT), those in the IgG-Fn-positive group showed higher pathological progression and greater incidence of inadequate response to NAT as compared to the IgG-Fn-negative group (odds ratio 0.48, 95% CI 0.24-0.92; p = 0.04). The present findings indicate that IgG-Fn can serve as a marker indicating poor tumor response to NAT in advanced ESCC cases.

Indexed as

Antibodies, BacterialCarcinoma, Squamous CellEsophageal NeoplasmsFusobacterium nucleatumImmunoglobulin GAdultAgedEsophageal Squamous Cell CarcinomaEsophagectomyFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPrognosisTreatment OutcomeAntibodies, BacterialImmunoglobulin G

Identifiers

PMID41270093
PMCPMC12637919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.